Classification of patients with GH disorders may vary according to the IGF-I assay.

Conclusion: Even when using normative data obtained in the same large population of healthy subjects and when using calculated IGF-I SD scores, agreement among IGF-I assay methods is only moderate to good. Differences in assay performance must be taken into account when evaluating and monitoring patients with GH disorders. This argues for the use of the same IGF-I assay for a given patient throughout follow-up.
PMID: 28505364 [PubMed - as supplied by publisher]

Source: The Journal of Clinical Endocrinology and Metabolism - May 12, 2017 Category: Endocrinology Authors: Mavromati M, Kuhn E, Agostini H, Brailly-Tabard S, Massart C, Piketty ML, Arnoux A, Young J, Souberbielle JC, Chanson P Tags: J Clin Endocrinol Metab Source Type: research